Study characteristics
| No. of patients . | Mean gestational age at entry, wk . | Thrombophilia included . | Inclusion criteria for pregnancy loss . | Treatment arm 1 . | Treatment arm 2 . | Treatment arm 3 . | Trial (year) . | Reference . |
|---|---|---|---|---|---|---|---|---|
| 160 | 8.0* | FVL, PGM, PS | 1 loss ≥10 wk | Enoxaparin 40 mg | ASA 100 mg | N/A | Gris et al (2004) | 16 |
| 19 | 5.7 | FVL, PGM, PC, PS, MTHRF | 2 losses <32 wk | Dalteparin 5000 IU + ASA 81 mg | ASA 81 mg | N/A | HepASA (2009) | 22 |
| 47 | 6.0* | FVL, PGM, PC, PS, AT | 2 losses ≤20 wk | Nadroparin 2850 IU + ASA 80 mg | ASA 80 mg† | Placebo | ALIFE (2010) | 17 |
| 10 | 6.0‡ | FVL, PGM, PC, PS, AT | 2 losses ≤24 wk | Enoxaparin 40 mg + ASA 75 mg | No treatment | N/A | SPIN (2010) | 15 |
| 26 | 5.2 | FVL, PGM, PC, PS | 3 losses <13 wk, 2 losses 13-24 wk, 1 loss >24 wk + 1 loss <13 wk | Enoxaparin 40 mg + ASA 100 mg | Enoxaparin 40 mg + placebo | ASA 100 mg | HABENOX (2011) | 23 |
| 23 | 11.0 | FVL, PGM, PC, PS, AT | 1 loss >15 wk | Nadroparin 3800 IU | No treatment | N/A | HAPPY (2012) | 24 |
| 143 | 11.9 | FVL, PGM, PC, PS, AT | 3 losses <10 wk, 2 losses 10-16 wk, 1 loss ≥16 wk | Dalteparin 5000 IU§ (ASA allowed) | No treatment (ASA allowed) | N/A | TIPPS (2014) | 25 |
| 55 | 7.0 | FVL, PGM, PC, PS, AT | 2 losses <12 wk, 1 loss ≥12 wk | Dalteparin 5000 IU | No treatment | N/A | ETHIG II (2015) | 26 |
| No. of patients . | Mean gestational age at entry, wk . | Thrombophilia included . | Inclusion criteria for pregnancy loss . | Treatment arm 1 . | Treatment arm 2 . | Treatment arm 3 . | Trial (year) . | Reference . |
|---|---|---|---|---|---|---|---|---|
| 160 | 8.0* | FVL, PGM, PS | 1 loss ≥10 wk | Enoxaparin 40 mg | ASA 100 mg | N/A | Gris et al (2004) | 16 |
| 19 | 5.7 | FVL, PGM, PC, PS, MTHRF | 2 losses <32 wk | Dalteparin 5000 IU + ASA 81 mg | ASA 81 mg | N/A | HepASA (2009) | 22 |
| 47 | 6.0* | FVL, PGM, PC, PS, AT | 2 losses ≤20 wk | Nadroparin 2850 IU + ASA 80 mg | ASA 80 mg† | Placebo | ALIFE (2010) | 17 |
| 10 | 6.0‡ | FVL, PGM, PC, PS, AT | 2 losses ≤24 wk | Enoxaparin 40 mg + ASA 75 mg | No treatment | N/A | SPIN (2010) | 15 |
| 26 | 5.2 | FVL, PGM, PC, PS | 3 losses <13 wk, 2 losses 13-24 wk, 1 loss >24 wk + 1 loss <13 wk | Enoxaparin 40 mg + ASA 100 mg | Enoxaparin 40 mg + placebo | ASA 100 mg | HABENOX (2011) | 23 |
| 23 | 11.0 | FVL, PGM, PC, PS, AT | 1 loss >15 wk | Nadroparin 3800 IU | No treatment | N/A | HAPPY (2012) | 24 |
| 143 | 11.9 | FVL, PGM, PC, PS, AT | 3 losses <10 wk, 2 losses 10-16 wk, 1 loss ≥16 wk | Dalteparin 5000 IU§ (ASA allowed) | No treatment (ASA allowed) | N/A | TIPPS (2014) | 25 |
| 55 | 7.0 | FVL, PGM, PC, PS, AT | 2 losses <12 wk, 1 loss ≥12 wk | Dalteparin 5000 IU | No treatment | N/A | ETHIG II (2015) | 26 |
ASA, aspirin; AT, antithrombin deficiency; MTHRF, methylenetetrahydrofolate reductase; N/A, not applicable; PC, protein C deficiency; PGM, prothrombin gene mutation; PS, protein S deficiency.
Gestational age when LMWH was initiated.
Calcium carbasalate 100 mg daily is equivalent to aspirin 80 mg daily.
Gestational age at study entry reported as median.
Dalteparin 5000 IU dosed once daily until 20 wk, and then twice daily until at least 37 wk gestation.